课题基金 / 基金详情

Methodologic Innovations in Cancer Epidemiology

Methodologic Innovations in Cancer Epidemiology
癌症流行病学的方法创新
批准号:
10655958
负责人:
Bernard A Rosner
金额:
$48.69万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-03-01 至 2027-02-28

项目摘要

项目成果

Bernard A Rosner的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Cancers take many years to develop, and death due to a cancer may occur many years after diagnosis. Therefore, it is important to use innovative methods of analysis to make optimal use of all exposure data both before and after diagnosis. We propose four types of innovations in the current application. Lethal cancer models: Of highest public health interest is what risk factors predispose a disease-free subject to die due to a specific cancer in the future. We have previously developed models for lethal cancer by integrating models for cancer incidence with models for prognosis after a cancer diagnosis. In this application, we propose to extend this approach in the case of colorectal cancer (CRC) by considering three stages in the carcinogenic process: (a) development of advanced polyp, (b) development of incident CRC after advanced polyp have been identified and removed, and (c) death due to CRC among patients with incident CRC. Latency models: Some prospective studies have risk factor data available at several points in time. One issue is how these data should be optimally used to predict cancer incidence. One approach is to use the most recent exposure; a 2nd approach is to use the total duration of exposure; a 3rd approach is to introduce a lag between exposure and outcome assessment. In this application, we propose a latency model to estimate the optimal weighting of previous exposures to predict cancer incidence; these models enhance understanding of biological mechanisms for specific risk factors. Cure Models: There have been many studies of risk factors predicting mortality among cancer patients. However, for some cancers, if patients do not die from their cancer over a given period of time (e.g., within 5 years for CRC), then they are unlikely to ever die due to their cancer, and will probably die due to another cause (i.e., they are cured). But what are the risk factors that predict cure? Although cure models have been used before, they mostly are based on post-diagnostic risk factors. To our knowledge, this is the 1st proposal to consider pre-diagnostic risk factors as predictors of cure. Assessing Effects of Screening on CRC risk models: Colonoscopy is the current standard for CRC screening. It is unique, in that if pre-cancerous lesions (i.e., adenomas) are found, then they are removed, and the natural history of CRC progression is interrupted. However, even if these lesions are removed, for some subjects, these lesions are more likely to develop again at a future time. Thus, it is challenging how to control for effects of screening in CRC risk models. In this application, we propose an innovative approach to control for screening by both assessing effects of a risk factor on adenoma incidence, and effects of adenoma incidence on CRC risk.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nonparametric and Survival Methods in Ophthalmology
  • 批准号:
    8926995
  • 项目类别:
  • 资助金额:
    $37.54万
  • 财政年份:
    2013
  • 负责人:
    Bernard A Rosner
  • 依托单位:
Nonparametric and Survival Methods in Ophthalmology
  • 批准号:
    8504222
  • 项目类别:
  • 资助金额:
    $42.35万
  • 财政年份:
    2013
  • 负责人:
    Bernard A Rosner
  • 依托单位:
Nonparametric and Survival Methods in Ophthalmology
  • 批准号:
    8728251
  • 项目类别:
  • 资助金额:
    $37.6万
  • 财政年份:
    2013
  • 负责人:
    Bernard A Rosner
  • 依托单位:
Use of Correlated Data Methods in Ophthalmology
  • 批准号:
    10542387
  • 项目类别:
  • 资助金额:
    $48.44万
  • 财政年份:
    2013
  • 负责人:
    Bernard A Rosner
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: